{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:56:47Z","timestamp":1781650607955,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venous thromboembolism is a potentially life-threatening condition, with patients having active malignancy at a 12-fold higher risk. Hospital-acquired VTE contributes to mortality, morbidity, and prolonged hospitalization. The 2024 British Society for Haematology guidelines recommend VTE risk assessment and prophylaxis within 24 h of admission. This audit evaluated adherence to these guidelines among oncology inpatients, aiming to identify gaps and opportunities for standardizing VTE management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective audit was conducted on 99 oncology inpatients. Electronic records, admission documentation, and drug charts were reviewed for VTE risk assessment completion and timing, prescription and appropriateness of pharmacological prophylaxis, 24-h reassessment, and adherence to cancer-associated thrombosis treatment standards. Patients with documented contraindications to anticoagulation were excluded from adherence analyses. Data were compared with BSH 2024 recommendations, and frequencies and percentages were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      VTE risk assessment was documented in 64.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964) of patients, while 35.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935) had no recorded assessment or reassessment. Among assessed patients, 57.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200937) were high risk, 28.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) low risk, and 14.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) high bleeding risk. Pharmacological prophylaxis was prescribed in 71.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200971) of patients, initiated within 14 h in 36.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926), and appropriately selected in 88.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) of those receiving timely prophylaxis. Reassessment within 24 h occurred in 12.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) of patients. Hospital-acquired thrombosis was identified in 6.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) of patients, with prophylaxis adherence varying across services: 71.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200971) in medical oncology, 26.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) in surgical oncology, and 11.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) in myeloma pathways. Catheter-related thrombosis prevention was documented in 4.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). For CAT management, 69.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200969) received anticoagulation during the first six months and continued beyond six months if the malignancy remained active. Recurrent VTE occurred in 22.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) of patients receiving complete treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical practice in this oncology department largely aligns with BSH 2024 recommendations; however, documentation is inconsistent and incomplete. Standardized electronic templates, mandatory assessment fields, clarified myeloma pathways, and targeted staff education may improve adherence. A follow-up re-audit is recommended to evaluate progress and reinforce guideline implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16042-x","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:56:24Z","timestamp":1776653784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venous thromboembolism risk assessment and prophylaxis in cancer patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Krish","family":"Nebhnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2602-6637","authenticated-orcid":false,"given":"Salman","family":"Muhammad Soomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabeeha","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"16042_CR1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1186\/s12913-025-13126-5","volume":"25","author":"AG Parmar","year":"2025","unstructured":"Parmar AG, Soomar SM, Mahen R, Shahid AB, Alharazi N, Akhlaque F, et al. VTE risk assessment and management in admitted patients at a private hospital in Dubai-A quality improvement project. BMC Health Serv Res. 2025;25(1):1084.","journal-title":"BMC Health Serv Res"},{"issue":"10294","key":"16042_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","volume":"398","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398(10294):64\u201377.","journal-title":"Lancet"},{"issue":"2","key":"16042_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/SLA.0b013e3181c0e58f","volume":"251","author":"AK Kakkar","year":"2010","unstructured":"Kakkar AK, Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg. 2010;251(2):330\u20138.","journal-title":"Ann Surg"},{"issue":"10","key":"16042_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB AbdolRazak","year":"2018","unstructured":"AbdolRazak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10):380.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"16042_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490\u20133.","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"16042_CR6","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","volume":"135","author":"A Falanga","year":"2015","unstructured":"Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015;135(Suppl 1):S8-s11.","journal-title":"Thromb Res"},{"key":"16042_CR7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S0049-3848(20)30408-4","volume":"191","author":"R Cantrell","year":"2020","unstructured":"Cantrell R, Palumbo JS. The thrombin\u2013inflammation axis in cancer progression. Thromb Res. 2020;191:S117\u201322.","journal-title":"Thromb Res"},{"issue":"4","key":"16042_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/13696998.2019.1703190","volume":"23","author":"AA Khorana","year":"2020","unstructured":"Khorana AA, McCrae KR, Milentijevic D, Lalibert\u00e9 F, Lejeune D, Crivera C, et al. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. J Med Econ. 2020;23(4):323\u20139.","journal-title":"J Med Econ"},{"issue":"1","key":"16042_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"16042_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bcmd.2005.12.008","volume":"36","author":"N Mackman","year":"2006","unstructured":"Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36(2):104\u20137.","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"16042_CR11","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275.","journal-title":"PLoS Med."},{"issue":"5","key":"16042_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496\u2013520.","journal-title":"J Clin Oncol"},{"key":"16042_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","volume":"137","author":"SD Grosse","year":"2016","unstructured":"Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3\u201310.","journal-title":"Thromb Res"},{"issue":"7","key":"16042_CR14","doi-asserted-by":"publisher","first-page":"e095072","DOI":"10.1136\/bmjopen-2024-095072","volume":"15","author":"A Rayan","year":"2025","unstructured":"Rayan A, Sisan M, Nashwan A, Deeb AM, Awad M, Baqeas M. To what extent do cancer centres in Arab countries adhere to ASCO\/ONS chemotherapy administration safety standards? A multicentre cross-sectional study. BMJ Open. 2025;15(7):e095072.","journal-title":"BMJ Open"},{"issue":"sup1","key":"16042_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/07357900802656681","volume":"27","author":"T Wun","year":"2009","unstructured":"Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009;27(sup1):63\u201374.","journal-title":"Cancer Invest"},{"issue":"14","key":"16042_CR16","first-page":"1959","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e0th-Puh\u00f3 E, van Es N, Van Laarhoven H, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood J Am Soc Hematol. 2021;137(14):1959\u201369.","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"16042_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"16042_CR18","doi-asserted-by":"publisher","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","volume":"25","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Eldredge JB, Anand LN, Zhang M, Qiu M, Nourabadi S, et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist. 2020;25(7):e1083\u201390.","journal-title":"Oncologist"},{"issue":"1","key":"16042_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11239-023-02817-7","volume":"56","author":"IHF da Costa","year":"2023","unstructured":"da Costa IHF, de P\u00e1dua CAM, de Miranda Drummond PL, Silveira LP, Malta JS, Dos Santos RMM, et al. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: A Brazilian historical cohort. J Thromb Thrombolysis. 2023;56(1):147\u201355.","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"16042_CR20","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1055\/s-0040-1705137","volume":"4","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, et al. Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH open. 2020;4(01):e59\u201365.","journal-title":"TH open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16042-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:23:33Z","timestamp":1781648613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16042"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16042-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the ethical requirements were fulfilled under the \u201cDeclaration of Helsinki.\u201d Ethical approval of the study was obtained from the Ethical Review Committee of King\u2019s College Hospital London, Dubai, UAE (KCH-REC-086). Informed written consent was waived by the Ethical Review Committee of King\u2019s College Hospital London, Dubai, UAE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"683"}}